| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | BMZ announces production results for the first four months of 2024 | - | SteelRadar | ||
| 01.06. | Gerdau closes two plants in Brazil | 2 | SteelRadar | ||
| 01.06. | Tata Steel shows growth in the first quarter of 2024 | - | SteelRadar | ||
| 01.06. | TC&xDC;D: Crude steel production increased by 4.4% in April | - | SteelRadar | ||
| 01.06. | Billet market remained stagnant in Southeast Asia | - | SteelRadar | ||
| 01.06. | EU steel protection measures will continue to affect Korea | - | SteelRadar | ||
| 01.06. | Idaho Copper Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.06. | High Sierra Technologies, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 01.06. | Summit Midstream Corp - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 01.06. | EVOME MEDICAL TECHNOLOGIES INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.06. | Getaround, Inc - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 01.06. | Affimed N.V.: Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort | 129 | GlobeNewswire (Europe) | In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing... ► Artikel lesen | |
| 01.06. | Prospera Energy Inc. Announces 2023 Financial Results | 27 | GlobeNewswire (Europe) | CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. ("Prospera" or the "Corporation") (PEI: TSX-V; OF6A: FRA) 2023 was a transformational year for Prospera transforming to horizontal... ► Artikel lesen | |
| 01.06. | Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 34 | GlobeNewswire (Europe) | Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial... ► Artikel lesen | |
| 01.06. | Corbus Pharmaceuticals Holdings, Inc.: SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presente | 19 | GlobeNewswire (Europe) | An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR... ► Artikel lesen | |
| 01.06. | Genmab A/S: Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) | 53 | GlobeNewswire (Europe) | Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS)... ► Artikel lesen | |
| 01.06. | Y-mAbs Therapeutics, Inc.: Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting | 23 | GlobeNewswire (Europe) | NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| 01.06. | Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 | 42 | GlobeNewswire (Europe) | Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly... ► Artikel lesen | |
| 01.06. | Purple Biotech Ltd.: Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer | 50 | GlobeNewswire (Europe) | 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC)... ► Artikel lesen | |
| 01.06. | Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting | 31 | GlobeNewswire (Europe) | KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 3.968 |
| EVOTEC | 3.343 |
| TUI | 2.191 |
| GAMESTOP | 2.057 |
| NEL | 1.952 |
| BAYER | 1.638 |
| BYD | 1.519 |
| RHEINMETALL | 1.345 |
| SMA SOLAR | 1.308 |
| CAVENDISH HYDROGEN | 1.175 |
| DEUTSCHE LUFTHANSA | 1.165 |
| AIXTRON SE | 986 |
| TESLA | 974 |
| SUPER MICRO COMPUTER | 897 |
| VOLKSWAGEN | 797 |
| THYSSENKRUPP | 720 |
| PALANTIR TECHNOLOGIES | 696 |
| DEFI TECHNOLOGIES | 686 |
| APPLE | 654 |
| BASF | 646 |
| BIONTECH | 631 |
| CARL ZEISS MEDITEC | 604 |
| HEIDELBERGER DRUCK | 595 |
| RENK GROUP | 590 |
| DEUTSCHE BANK | 589 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
